目的探讨诺和锐30与诺和灵30R对于住院初诊的2型糖尿病患者的治疗效果。方法回顾性分析2010年5月一2012年9月我院收治的60例初诊T2DM患者，根据患者当时接受的治疗方法分为诺和锐30组与诺和灵30R组，各30例，两组患者分别以诺和锐30和诺和灵30R进行治疗，在经过一段时间治疗以后对患者的疗效进行观察对比。结果两组患者相对于接受治疗前，空腹血糖（FPG）、糖化血糖蛋白（HbAlC）以及餐后2h血糖（2hPBG）均有明显的下降，但是诺和锐30组的患者在HbAlC以及2hPBG方面下降更为显著（P〈0．01；P〈0．05）；对血糖进行控制的前提上诺和锐30剂量相对于诺和灵30R少很多（P〈0．05）；诺和锐30组患者出现低血糖概率相对于诺和灵30R组别患者要低（P〈O．05）。结论诺和锐30以及诺和灵30R均有着降低血糖指数的效果，但与诺和灵30R相比，诺和锐30对于T2DM患者在血糖水平及低血糖反应方面有着更加突出的优越性。

Objective To explore and analyze the clinical efficacy of Novomix30 and pre-mixed30R in the treatment of type 2 diabetes mellitus (T2DM). Methods 60 cases with T2DM in our hospital from May 2010 to September 2012 were selected and retrospectively analyzed,the patients were divided into Novomix30 group and pre-mixed30R group according to the treatment they received,each group had 30 cases, the two groups were treated by Novomix30 and pre-mixed30R respectively.Observed and compared the efficacy of the two groups after a period of treatment. Results compared with before the treatment, FPG,HbA1C and 2hPBG of the two groups had both decreased significantly,but HbA1C and 2hPBG in Novomix30 group decreased more significantly(P<0.01;P<0.05),hypoglycemia probability in Novomix30 group was lower than that in pre-mixed30R group(P < 0.05). Conclusion Novomix30 and pre-mixed30R both can reduce glycemic index,but compare with pre-mixed30R,Novomix30 in blood sugar levels and hypoglycemia reaction for

目的：混合门冬胰岛素302次/d注射（诺和锐30）与预混人胰岛素（诺和灵30R 30R）在2型糖尿病患者治疗的安全性的疗效。方法68例口服降糖药控制不佳的2型糖尿病患者随机分为两组，诺和锐30治疗组与诺和灵30R治疗组，分别，每日早餐前晚餐前诺和锐30与诺和灵30R注射。观察12 w。比较两组患者的糖化血红蛋白（HbAlc），血糖，低血糖的频率等。结果早期诺和锐30治疗组。餐后血糖显著低于诺和灵30R治疗组（P＜0.01）；门冬胰岛素30治疗组低血糖比诺和灵30R治疗组少，但差异无统计学意义（P＞0.05），门冬胰岛素治疗组无严重低血糖。结论2型糖尿病患者。2次/d注射门冬胰岛素30比诺和灵30R显著降低餐后血糖，降低低血糖风险，易为患者接受。

Objective Mixed insulin aspart 302 infusions of /d (Nuo Herui 30) mixed human insulin (Novolin 30R and pre 30R) on the ef icacy and safety of treatment of type 2 diabetic patients. Methods 68 cases of oral antidiabetic drug control in type 2 diabetic patients were randomly divided into two groups of poor, insulin aspart 30 in treatment group and Nuo Heling 30R treatment group, respectively, every morning before breakfast before supper insulin aspart 30 and Nuo Heling 30R injection. Observation of 12 W. Comparing the two groups of patients with glycosylated hemoglobin (HbAlc), blood glucose, and frequency of hypoglycemia etc. Results The early insulin aspart 30 in the treatment group. Postprandial blood glucose was significantly lower than that of Novolin 30R treated group (P 0.05), insulin aspart treatment group without severe hypoglycemia. Conclusion Patients with type 2 diabetes mel itus. The 2 /d injection of insulin aspart 30 Noir and spirit of 30R significantly decreased the postp

目的探讨来得时联合拜唐苹和诺和锐30治疗高龄（80岁以上）2型糖尿病（T2DM）患者血糖、糖化血红蛋白（HbAlC）变化，低血糖事件发生率及临床意义。方法将120例口服降糖药物疗效较差的高龄T2DM患者随机分为来得时联合拜唐苹组和诺和锐30组（每组60例）。来得时联合拜唐苹组每日早餐前注射1次来得时加三餐中口服拜唐苹，诺和锐30组早晚餐前各皮下注射1次，共16周，比较两组患者空腹血糖（FBG）及餐后2小时血糖（2hPBG）、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C），高密度脂蛋白胆固醇（HDL．C）、HbAlc的下降情况，低血糖事件发生率。结果两组治疗前后血糖、TG、TC、LDL．C、HbAlc下降明显，其中来得时联合拜唐苹组HbA1c从（8．8％±2．0％）下降至（7．1％±1．2％）；诺和锐30组HbA1c从（8．9％±2．4％）下降到（7．0％±1．2％）；治疗后两组之间差异无统计学意义（P〉0．05）；来得时联合拜唐苹组低血糖事件发生率明显低于诺和锐30组（3．3％vs13．3％，P〈0．01）。结论来得时联合拜唐苹组和诺和锐30组都具有明显降低FBG、2hPBG、TG、TC、LDL．C、HbAlc的作用，来得时联合拜唐苹组低血糖事件发生率明显低于诺和锐30组。

Objective To investigate the changes of blood glucose, HbA1c, and incidence of hypoglycemia in the very old patients (over 80 years) with type 2 diabetes mellitus (T2DM) after the treatment of lantus with glucobay or Novomix 30, and the clinical significance. Methods A total of 120 very old T2DM patients poorly controlled with oral hypoglycemic drugs admitted in our department from July 2011 to June 2012 were subjected in this study. They were randomly divided into lantus with glucobay group and Novomix 30 group (n=60 in each group). Lantus was injected before breakfast, and glucobay was taken with meals, while Novomix 30 was injected before morning and evening meals for total 16 weeks. Fasting blood glucose (FBG) and 2-hour postprandial blood glucose (2hPBG), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), the decrease of HbA1c, and the incidence of hypoglycemia were compared between the two groups.

目的比较地特胰岛素联合格列齐特缓释片与诺和锐30治疗2型糖尿病患者的疗效。方法选择80例继发性磺脲类降糖药失效的2型糖尿病患者，随机分为地特胰岛素联合格列齐特缓释片组和诺和锐30治疗组。观察两组治疗前后血糖及HbA1c变化，以及低血糖发生率。结果两组各监测点血糖及HbA1c治疗后与治疗前比较均明显下降(P 0.05)。结论地特胰岛素联合格列齐特缓释片与诺和锐30均能有效控制血糖，两组低血糖发生率低且相近。

Objective To study the therapeutic effects of insulin detemir combined with gliclazide sustained-release tablets and insulin aspart30 in treating type 2 diabetes melitus. Methods 80 type 2 diabetes patients with secondary failure to sulfonylureas(SFS) were grouped randomly by insulin detemir combined with gliclazide sustained-release tablets ,insulin aspart30 for 3 months. The blood glucose and HbA1c before and after treatment were observed. And the incidence of hypoglycemia were compared. Result There were statisticaly significant differences in blood glucose at various points in 24 hours and in HbA1c between the two groups before and after treatment (P 0.05) .Conclusion The above two treatments can reduce the blood glucose and HbA1c effectively. The incidence of hypoglycemia in insulin detemir combined with gliclazide sustained-release tablets was as low as in insulin aspart30.

目的：探究与分析诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效。方法选取本院自2012年12月~2013年11月收治的初诊重度2型糖尿病患者60例,将其作为临床研究对象,采取随机数字表法分为对照组和观察组,每组各30例,对照组给予诺和锐30治疗,观察组在其基础上加用维格列汀治疗,观察与对比两组患者的临床疗效。结果两组患者治疗后空腹血糖、餐后血糖、HbA1c、甘油三酯、总胆固醇、低密度脂蛋白胆固醇较治疗前显著降低,差异有统计学意义(P<0.05),观察组较对照组降低显著, P<0.05,差异具有统计学意义。结论诺和锐30联合维格列汀治疗初诊重度2型糖尿病的临床疗效显著,能够全面降低患者血糖,不良反应少,低血糖发生率低。

Objective To explore and analyze clinical effect of aspart 30 combined with vildagliptin in the treatment of newly diagnosed severe type 2 diabetes. Methods From December 2012 to November 2013, 60 cases of newly diagnosed severe type 2 diabetic patients were randomly divided into control group and observation group, 30 cases for each group, control group were given aspart treatment, observation group received vildagliptin treatment on its basis, and clinical efficacy of two groups was compared. Results After treatment, levels of fasting plasma glucose, postprandial glucose, HbA1c, TG, TC and LDL-C in observation group decreased significantly compared with control group, P<0.05, statistically significant. Conclusion Aspart 30 combined with vildagliptin therapy can significantly decrease blood sugar of newly severe diagnosed type 2 diabetes with less adverse reaction and low rates of hypoglycemia.